RETRACTED: Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG) Article Swipe
Elżbieta Kalicińska
,
Paula Jabłonowska-Babij
,
Marta Morawska
,
Elżbieta Iskierka‐Jazdzewska
,
Joanna Drozd‐Sokołowska
,
Ewa Paszkiewicz‐Kozik
,
Łukasz Szukalski
,
Judyta Strzała
,
Urszula Gosik
,
Jakub Dębski
,
Iga Andrasiak
,
Anna Skotny
,
Krzysztof Jamroziak
,
Tomasz Wróbel
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.3390/cancers16244168
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.3390/cancers16244168
Background/Objectives: Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes. Aims: The aims of this study were to assess the following: (1) the incidence of pneumonia in CLL patients treated with venetoclax-based regimens in a real-world setting, (2) the risk factors for event-free survival (EFS), and (3) overall survival (OS). Methods: This multicenter study included 322 patients from eight centers. Univariable and multivariable analyses (MVA) were performed, with the development of pneumonia during venetoclax-based treatment and OS as outcomes. Results: The most common complication was neutropenia (59%). During treatment with venetoclax-based regimens, 66 (20%) patients developed pneumonia—50 (23%) patients in the rituximab-plus-venetoclax (R-VEN) group and 13 (16%) patients in the obinutuzumab-plus-venetoclax (O-VEN) group (p = 0.15). Chronic obstructive pulmonary disease (COPD)/asthma, splenomegaly, elevated creatinine, and anemia < 8 g/dL were the risk factors for EFS in MVA (HR = 2.08, 95%CI 1.16–3.74, p = 0.014; HR 1.73, 95%CI 1.08–2.78, p = 0.02; HR 2.13, 95%CI 1.10–4.11, p = 0.03, HR 3.58, 95%CI 2.18–5.89, p < 0.001, respectively). Relapsed/refractory (R/R) CLL patients treated with R-VEN with pneumonia had worse OS than those without (p < 0.001). In patients treated with O-VEN, median OS did not differ between patients with and without pneumonia (p = 0.45). Conclusions: Our real-world study showed that pneumonia during venetoclax treatment occurs more frequently than reported in registration trials and has a negative impact on OS, especially in patients with R/R CLL who are treated with R-VEN. Neutropenia is not a risk factor for pneumonia.
Related Topics
Concepts
Venetoclax
Medicine
Internal medicine
Neutropenia
Chronic lymphocytic leukemia
Gastroenterology
Pneumonia
Obinutuzumab
Febrile neutropenia
Rituximab
Leukemia
Chemotherapy
Lymphoma
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3390/cancers16244168
- OA Status
- gold
- Cited By
- 2
- References
- 22
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4405424684
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4405424684Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3390/cancers16244168Digital Object Identifier
- Title
-
RETRACTED: Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG)Work title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-12-13Full publication date if available
- Authors
-
Elżbieta Kalicińska, Paula Jabłonowska-Babij, Marta Morawska, Elżbieta Iskierka‐Jazdzewska, Joanna Drozd‐Sokołowska, Ewa Paszkiewicz‐Kozik, Łukasz Szukalski, Judyta Strzała, Urszula Gosik, Jakub Dębski, Iga Andrasiak, Anna Skotny, Krzysztof Jamroziak, Tomasz WróbelList of authors in order
- Landing page
-
https://doi.org/10.3390/cancers16244168Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.3390/cancers16244168Direct OA link when available
- Concepts
-
Venetoclax, Medicine, Internal medicine, Neutropenia, Chronic lymphocytic leukemia, Gastroenterology, Pneumonia, Obinutuzumab, Febrile neutropenia, Rituximab, Leukemia, Chemotherapy, LymphomaTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
2Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 2Per-year citation counts (last 5 years)
- References (count)
-
22Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4405424684 |
|---|---|
| doi | https://doi.org/10.3390/cancers16244168 |
| ids.doi | https://doi.org/10.3390/cancers16244168 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39766067 |
| ids.openalex | https://openalex.org/W4405424684 |
| fwci | 1.90345994 |
| type | article |
| title | RETRACTED: Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG) |
| biblio.issue | 24 |
| biblio.volume | 16 |
| biblio.last_page | 4168 |
| biblio.first_page | 4168 |
| grants[0].funder | https://openalex.org/F4320325938 |
| grants[0].award_id | |
| grants[0].funder_display_name | Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu |
| topics[0].id | https://openalex.org/T11157 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2716 |
| topics[0].subfield.display_name | Genetics |
| topics[0].display_name | Chronic Lymphocytic Leukemia Research |
| topics[1].id | https://openalex.org/T11725 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9746999740600586 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Immunodeficiency and Autoimmune Disorders |
| topics[2].id | https://openalex.org/T10401 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9699000120162964 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2712 |
| topics[2].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[2].display_name | Diabetes Treatment and Management |
| funders[0].id | https://openalex.org/F4320325938 |
| funders[0].ror | https://ror.org/01qpw1b93 |
| funders[0].display_name | Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu |
| is_xpac | False |
| apc_list.value | 2400 |
| apc_list.currency | CHF |
| apc_list.value_usd | 2598 |
| apc_paid.value | 2400 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 2598 |
| concepts[0].id | https://openalex.org/C2779675984 |
| concepts[0].level | 4 |
| concepts[0].score | 0.939908504486084 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q23671272 |
| concepts[0].display_name | Venetoclax |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.7778626084327698 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C126322002 |
| concepts[2].level | 1 |
| concepts[2].score | 0.7430915832519531 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[2].display_name | Internal medicine |
| concepts[3].id | https://openalex.org/C2777063308 |
| concepts[3].level | 3 |
| concepts[3].score | 0.6133738160133362 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1435822 |
| concepts[3].display_name | Neutropenia |
| concepts[4].id | https://openalex.org/C2777938653 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5241173505783081 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1088156 |
| concepts[4].display_name | Chronic lymphocytic leukemia |
| concepts[5].id | https://openalex.org/C90924648 |
| concepts[5].level | 1 |
| concepts[5].score | 0.5110007524490356 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[5].display_name | Gastroenterology |
| concepts[6].id | https://openalex.org/C2777914695 |
| concepts[6].level | 2 |
| concepts[6].score | 0.510572075843811 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q12192 |
| concepts[6].display_name | Pneumonia |
| concepts[7].id | https://openalex.org/C2777607594 |
| concepts[7].level | 4 |
| concepts[7].score | 0.4380861818790436 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q389496 |
| concepts[7].display_name | Obinutuzumab |
| concepts[8].id | https://openalex.org/C2778850193 |
| concepts[8].level | 4 |
| concepts[8].score | 0.43588322401046753 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q3775974 |
| concepts[8].display_name | Febrile neutropenia |
| concepts[9].id | https://openalex.org/C2780653079 |
| concepts[9].level | 3 |
| concepts[9].score | 0.4260963201522827 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q412323 |
| concepts[9].display_name | Rituximab |
| concepts[10].id | https://openalex.org/C2778461978 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4046076238155365 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q29496 |
| concepts[10].display_name | Leukemia |
| concepts[11].id | https://openalex.org/C2776694085 |
| concepts[11].level | 2 |
| concepts[11].score | 0.17810985445976257 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[11].display_name | Chemotherapy |
| concepts[12].id | https://openalex.org/C2779338263 |
| concepts[12].level | 2 |
| concepts[12].score | 0.16686448454856873 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[12].display_name | Lymphoma |
| keywords[0].id | https://openalex.org/keywords/venetoclax |
| keywords[0].score | 0.939908504486084 |
| keywords[0].display_name | Venetoclax |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.7778626084327698 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/internal-medicine |
| keywords[2].score | 0.7430915832519531 |
| keywords[2].display_name | Internal medicine |
| keywords[3].id | https://openalex.org/keywords/neutropenia |
| keywords[3].score | 0.6133738160133362 |
| keywords[3].display_name | Neutropenia |
| keywords[4].id | https://openalex.org/keywords/chronic-lymphocytic-leukemia |
| keywords[4].score | 0.5241173505783081 |
| keywords[4].display_name | Chronic lymphocytic leukemia |
| keywords[5].id | https://openalex.org/keywords/gastroenterology |
| keywords[5].score | 0.5110007524490356 |
| keywords[5].display_name | Gastroenterology |
| keywords[6].id | https://openalex.org/keywords/pneumonia |
| keywords[6].score | 0.510572075843811 |
| keywords[6].display_name | Pneumonia |
| keywords[7].id | https://openalex.org/keywords/obinutuzumab |
| keywords[7].score | 0.4380861818790436 |
| keywords[7].display_name | Obinutuzumab |
| keywords[8].id | https://openalex.org/keywords/febrile-neutropenia |
| keywords[8].score | 0.43588322401046753 |
| keywords[8].display_name | Febrile neutropenia |
| keywords[9].id | https://openalex.org/keywords/rituximab |
| keywords[9].score | 0.4260963201522827 |
| keywords[9].display_name | Rituximab |
| keywords[10].id | https://openalex.org/keywords/leukemia |
| keywords[10].score | 0.4046076238155365 |
| keywords[10].display_name | Leukemia |
| keywords[11].id | https://openalex.org/keywords/chemotherapy |
| keywords[11].score | 0.17810985445976257 |
| keywords[11].display_name | Chemotherapy |
| keywords[12].id | https://openalex.org/keywords/lymphoma |
| keywords[12].score | 0.16686448454856873 |
| keywords[12].display_name | Lymphoma |
| language | en |
| locations[0].id | doi:10.3390/cancers16244168 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S168415115 |
| locations[0].source.issn | 2072-6694 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2072-6694 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Cancers |
| locations[0].source.host_organization | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310310987 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Cancers |
| locations[0].landing_page_url | https://doi.org/10.3390/cancers16244168 |
| locations[1].id | pmid:39766067 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Cancers |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39766067 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:11674704 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Cancers (Basel) |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11674704 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5085929018 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-4797-8001 |
| authorships[0].author.display_name | Elżbieta Kalicińska |
| authorships[0].countries | PL |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I385303915 |
| authorships[0].affiliations[0].raw_affiliation_string | Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland |
| authorships[0].institutions[0].id | https://openalex.org/I385303915 |
| authorships[0].institutions[0].ror | https://ror.org/01qpw1b93 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I385303915 |
| authorships[0].institutions[0].country_code | PL |
| authorships[0].institutions[0].display_name | Wroclaw Medical University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Elżbieta Kalicińska |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland |
| authorships[1].author.id | https://openalex.org/A5076183733 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6984-2116 |
| authorships[1].author.display_name | Paula Jabłonowska-Babij |
| authorships[1].countries | PL |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I385303915 |
| authorships[1].affiliations[0].raw_affiliation_string | Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland |
| authorships[1].institutions[0].id | https://openalex.org/I385303915 |
| authorships[1].institutions[0].ror | https://ror.org/01qpw1b93 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I385303915 |
| authorships[1].institutions[0].country_code | PL |
| authorships[1].institutions[0].display_name | Wroclaw Medical University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Paula Jabłonowska-Babij |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland |
| authorships[2].author.id | https://openalex.org/A5074479170 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-6836-2903 |
| authorships[2].author.display_name | Marta Morawska |
| authorships[2].countries | PL |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I121032520 |
| authorships[2].affiliations[0].raw_affiliation_string | Experimental Hematooncology Department, Medical University of Lublin, 20-059 Lublin, Poland |
| authorships[2].institutions[0].id | https://openalex.org/I121032520 |
| authorships[2].institutions[0].ror | https://ror.org/016f61126 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I121032520 |
| authorships[2].institutions[0].country_code | PL |
| authorships[2].institutions[0].display_name | Medical University of Lublin |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Marta Morawska |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Experimental Hematooncology Department, Medical University of Lublin, 20-059 Lublin, Poland |
| authorships[3].author.id | https://openalex.org/A5080511164 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-2772-8870 |
| authorships[3].author.display_name | Elżbieta Iskierka‐Jazdzewska |
| authorships[3].countries | PL |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210110173, https://openalex.org/I4210122071 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of General Hematology, Copernicus Memorial Hospital, Medical University of Lodz, 90-419 Lodz, Poland |
| authorships[3].institutions[0].id | https://openalex.org/I4210110173 |
| authorships[3].institutions[0].ror | https://ror.org/01m32d953 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210110173 |
| authorships[3].institutions[0].country_code | PL |
| authorships[3].institutions[0].display_name | Copernicus Memorial Hospital |
| authorships[3].institutions[1].id | https://openalex.org/I4210122071 |
| authorships[3].institutions[1].ror | https://ror.org/02t4ekc95 |
| authorships[3].institutions[1].type | education |
| authorships[3].institutions[1].lineage | https://openalex.org/I4210122071 |
| authorships[3].institutions[1].country_code | PL |
| authorships[3].institutions[1].display_name | Medical University of Lodz |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Elżbieta Iskierka-Jażdżewska |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of General Hematology, Copernicus Memorial Hospital, Medical University of Lodz, 90-419 Lodz, Poland |
| authorships[4].author.id | https://openalex.org/A5066581236 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-4562-6264 |
| authorships[4].author.display_name | Joanna Drozd‐Sokołowska |
| authorships[4].countries | PL |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I268303160 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland |
| authorships[4].institutions[0].id | https://openalex.org/I268303160 |
| authorships[4].institutions[0].ror | https://ror.org/04p2y4s44 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I268303160 |
| authorships[4].institutions[0].country_code | PL |
| authorships[4].institutions[0].display_name | Medical University of Warsaw |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Joanna Drozd-Sokołowska |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland |
| authorships[5].author.id | https://openalex.org/A5012308931 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-2629-3932 |
| authorships[5].author.display_name | Ewa Paszkiewicz‐Kozik |
| authorships[5].countries | PL |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210101740 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Lymphoid Malignancies, National Research Institute of Oncology, 02-781 Warsaw, Poland |
| authorships[5].institutions[0].id | https://openalex.org/I4210101740 |
| authorships[5].institutions[0].ror | https://ror.org/015qjap30 |
| authorships[5].institutions[0].type | facility |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210101740 |
| authorships[5].institutions[0].country_code | PL |
| authorships[5].institutions[0].display_name | Narodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Ewa Paszkiewicz-Kozik |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Lymphoid Malignancies, National Research Institute of Oncology, 02-781 Warsaw, Poland |
| authorships[6].author.id | https://openalex.org/A5019421016 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-9885-5140 |
| authorships[6].author.display_name | Łukasz Szukalski |
| authorships[6].countries | PL |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I3019271933, https://openalex.org/I4210148386 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-168 Toruń, Poland |
| authorships[6].institutions[0].id | https://openalex.org/I4210148386 |
| authorships[6].institutions[0].ror | https://ror.org/04c5jwj47 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I3019271933, https://openalex.org/I4210148386 |
| authorships[6].institutions[0].country_code | PL |
| authorships[6].institutions[0].display_name | Collegium Medicum in Bydgoszcz |
| authorships[6].institutions[1].id | https://openalex.org/I3019271933 |
| authorships[6].institutions[1].ror | https://ror.org/0102mm775 |
| authorships[6].institutions[1].type | education |
| authorships[6].institutions[1].lineage | https://openalex.org/I3019271933 |
| authorships[6].institutions[1].country_code | PL |
| authorships[6].institutions[1].display_name | Nicolaus Copernicus University |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Łukasz Szukalski |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-168 Toruń, Poland |
| authorships[7].author.id | https://openalex.org/A5087236321 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Judyta Strzała |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Hematology and Bone Marrow Transplantation, Pomeranian Hospitals in Gdynia, 81-519 Gdynia, Poland |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Judyta Strzała |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Hematology and Bone Marrow Transplantation, Pomeranian Hospitals in Gdynia, 81-519 Gdynia, Poland |
| authorships[8].author.id | https://openalex.org/A5114508397 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Urszula Gosik |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Hematology, St. John's Cancer Center in Lublin, 20-090 Lublin, Poland |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Urszula Gosik |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Hematology, St. John's Cancer Center in Lublin, 20-090 Lublin, Poland |
| authorships[9].author.id | https://openalex.org/A5046149757 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-2944-0929 |
| authorships[9].author.display_name | Jakub Dębski |
| authorships[9].countries | PL |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210101612 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Hematology, Provincial Specialist Hospital in Legnica, 59-220 Legnica, Poland |
| authorships[9].institutions[0].id | https://openalex.org/I4210101612 |
| authorships[9].institutions[0].ror | https://ror.org/0163kd003 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210101612 |
| authorships[9].institutions[0].country_code | PL |
| authorships[9].institutions[0].display_name | Witelon State University of Applied Sciences in Legnica |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Jakub Dębski |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Hematology, Provincial Specialist Hospital in Legnica, 59-220 Legnica, Poland |
| authorships[10].author.id | https://openalex.org/A5026487135 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-8415-8758 |
| authorships[10].author.display_name | Iga Andrasiak |
| authorships[10].affiliations[0].raw_affiliation_string | Individual Business Activity, ul. Zielna 28b/3, 51-313 Wroclaw, Poland |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Iga Andrasiak |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Individual Business Activity, ul. Zielna 28b/3, 51-313 Wroclaw, Poland |
| authorships[11].author.id | https://openalex.org/A5056310438 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-4167-0572 |
| authorships[11].author.display_name | Anna Skotny |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I136199984 |
| authorships[11].affiliations[0].raw_affiliation_string | Harvard T.H. Chan School of Public Health—Executive and Continuing Education, Harvard University, Boston, MA 02115, USA |
| authorships[11].institutions[0].id | https://openalex.org/I136199984 |
| authorships[11].institutions[0].ror | https://ror.org/03vek6s52 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I136199984 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Harvard University |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Anna Skotny |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Harvard T.H. Chan School of Public Health—Executive and Continuing Education, Harvard University, Boston, MA 02115, USA |
| authorships[12].author.id | https://openalex.org/A5039661217 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-7207-8534 |
| authorships[12].author.display_name | Krzysztof Jamroziak |
| authorships[12].countries | PL |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I268303160 |
| authorships[12].affiliations[0].raw_affiliation_string | Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland |
| authorships[12].institutions[0].id | https://openalex.org/I268303160 |
| authorships[12].institutions[0].ror | https://ror.org/04p2y4s44 |
| authorships[12].institutions[0].type | education |
| authorships[12].institutions[0].lineage | https://openalex.org/I268303160 |
| authorships[12].institutions[0].country_code | PL |
| authorships[12].institutions[0].display_name | Medical University of Warsaw |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Krzysztof Jamroziak |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland |
| authorships[13].author.id | https://openalex.org/A5030366119 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-6612-3535 |
| authorships[13].author.display_name | Tomasz Wróbel |
| authorships[13].countries | PL |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I385303915 |
| authorships[13].affiliations[0].raw_affiliation_string | Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland |
| authorships[13].institutions[0].id | https://openalex.org/I385303915 |
| authorships[13].institutions[0].ror | https://ror.org/01qpw1b93 |
| authorships[13].institutions[0].type | education |
| authorships[13].institutions[0].lineage | https://openalex.org/I385303915 |
| authorships[13].institutions[0].country_code | PL |
| authorships[13].institutions[0].display_name | Wroclaw Medical University |
| authorships[13].author_position | last |
| authorships[13].raw_author_name | Tomasz Wróbel |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.3390/cancers16244168 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | RETRACTED: Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG) |
| has_fulltext | False |
| is_retracted | True |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11157 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2716 |
| primary_topic.subfield.display_name | Genetics |
| primary_topic.display_name | Chronic Lymphocytic Leukemia Research |
| related_works | https://openalex.org/W2602605464, https://openalex.org/W3093108960, https://openalex.org/W3102573380, https://openalex.org/W4380150597, https://openalex.org/W4402585357, https://openalex.org/W4220918921, https://openalex.org/W4380084722, https://openalex.org/W2909116479, https://openalex.org/W4391389418, https://openalex.org/W4240222466 |
| cited_by_count | 2 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 2 |
| locations_count | 3 |
| best_oa_location.id | doi:10.3390/cancers16244168 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S168415115 |
| best_oa_location.source.issn | 2072-6694 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2072-6694 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Cancers |
| best_oa_location.source.host_organization | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Cancers |
| best_oa_location.landing_page_url | https://doi.org/10.3390/cancers16244168 |
| primary_location.id | doi:10.3390/cancers16244168 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S168415115 |
| primary_location.source.issn | 2072-6694 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2072-6694 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Cancers |
| primary_location.source.host_organization | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Cancers |
| primary_location.landing_page_url | https://doi.org/10.3390/cancers16244168 |
| publication_date | 2024-12-13 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W4390756152, https://openalex.org/W4283369890, https://openalex.org/W2800186514, https://openalex.org/W2792666902, https://openalex.org/W2948436219, https://openalex.org/W4382796842, https://openalex.org/W4391750319, https://openalex.org/W4226053409, https://openalex.org/W6809514361, https://openalex.org/W4391664903, https://openalex.org/W2520685252, https://openalex.org/W2010872995, https://openalex.org/W4280526462, https://openalex.org/W2810917981, https://openalex.org/W2781697927, https://openalex.org/W4389258259, https://openalex.org/W2171254410, https://openalex.org/W4379260082, https://openalex.org/W4308834958, https://openalex.org/W3080395306, https://openalex.org/W4283381819, https://openalex.org/W4221052789 |
| referenced_works_count | 22 |
| abstract_inverted_index.8 | 134 |
| abstract_inverted_index.= | 121, 145, 150, 157, 164, 209 |
| abstract_inverted_index.a | 41, 231, 250 |
| abstract_inverted_index.p | 149, 156, 163, 170 |
| abstract_inverted_index.(p | 120, 189, 208 |
| abstract_inverted_index.13 | 112 |
| abstract_inverted_index.66 | 99 |
| abstract_inverted_index.HR | 152, 159, 166 |
| abstract_inverted_index.In | 192 |
| abstract_inverted_index.OS | 83, 185, 198 |
| abstract_inverted_index.as | 84 |
| abstract_inverted_index.in | 33, 40, 106, 115, 142, 226, 237 |
| abstract_inverted_index.is | 248 |
| abstract_inverted_index.of | 20, 31, 77 |
| abstract_inverted_index.on | 234 |
| abstract_inverted_index.to | 9, 24 |
| abstract_inverted_index.(1) | 28 |
| abstract_inverted_index.(2) | 44 |
| abstract_inverted_index.(3) | 53 |
| abstract_inverted_index.(HR | 144 |
| abstract_inverted_index.322 | 62 |
| abstract_inverted_index.CLL | 34, 176, 241 |
| abstract_inverted_index.EFS | 141 |
| abstract_inverted_index.MVA | 143 |
| abstract_inverted_index.OS, | 235 |
| abstract_inverted_index.Our | 212 |
| abstract_inverted_index.R/R | 240 |
| abstract_inverted_index.The | 18, 87 |
| abstract_inverted_index.and | 52, 68, 82, 111, 131, 205, 229 |
| abstract_inverted_index.are | 7, 243 |
| abstract_inverted_index.can | 12 |
| abstract_inverted_index.did | 199 |
| abstract_inverted_index.for | 48, 140, 253 |
| abstract_inverted_index.had | 183 |
| abstract_inverted_index.has | 230 |
| abstract_inverted_index.not | 200, 249 |
| abstract_inverted_index.the | 26, 29, 45, 75, 107, 116, 137 |
| abstract_inverted_index.was | 91 |
| abstract_inverted_index.who | 242 |
| abstract_inverted_index.< | 133, 171, 190 |
| abstract_inverted_index.This | 58 |
| abstract_inverted_index.aims | 19 |
| abstract_inverted_index.from | 64 |
| abstract_inverted_index.g/dL | 135 |
| abstract_inverted_index.more | 222 |
| abstract_inverted_index.most | 88 |
| abstract_inverted_index.risk | 46, 138, 251 |
| abstract_inverted_index.than | 186, 224 |
| abstract_inverted_index.that | 11, 216 |
| abstract_inverted_index.this | 21 |
| abstract_inverted_index.were | 23, 72, 136 |
| abstract_inverted_index.with | 2, 37, 74, 96, 179, 181, 195, 204, 239, 245 |
| abstract_inverted_index.(16%) | 113 |
| abstract_inverted_index.(20%) | 100 |
| abstract_inverted_index.(23%) | 104 |
| abstract_inverted_index.(CLL) | 6 |
| abstract_inverted_index.(MVA) | 71 |
| abstract_inverted_index.(OS). | 56 |
| abstract_inverted_index.(R/R) | 175 |
| abstract_inverted_index.0.02; | 158 |
| abstract_inverted_index.0.03, | 165 |
| abstract_inverted_index.1.73, | 153 |
| abstract_inverted_index.2.08, | 146 |
| abstract_inverted_index.2.13, | 160 |
| abstract_inverted_index.3.58, | 167 |
| abstract_inverted_index.95%CI | 147, 154, 161, 168 |
| abstract_inverted_index.Aims: | 17 |
| abstract_inverted_index.R-VEN | 180 |
| abstract_inverted_index.eight | 65 |
| abstract_inverted_index.group | 110, 119 |
| abstract_inverted_index.study | 22, 60, 214 |
| abstract_inverted_index.their | 14 |
| abstract_inverted_index.those | 187 |
| abstract_inverted_index.worse | 184 |
| abstract_inverted_index.(59%). | 93 |
| abstract_inverted_index.(EFS), | 51 |
| abstract_inverted_index.0.001, | 172 |
| abstract_inverted_index.0.014; | 151 |
| abstract_inverted_index.0.15). | 122 |
| abstract_inverted_index.0.45). | 210 |
| abstract_inverted_index.During | 94 |
| abstract_inverted_index.O-VEN, | 196 |
| abstract_inverted_index.R-VEN. | 246 |
| abstract_inverted_index.affect | 13 |
| abstract_inverted_index.anemia | 132 |
| abstract_inverted_index.assess | 25 |
| abstract_inverted_index.common | 89 |
| abstract_inverted_index.differ | 201 |
| abstract_inverted_index.during | 79, 218 |
| abstract_inverted_index.factor | 252 |
| abstract_inverted_index.impact | 233 |
| abstract_inverted_index.median | 197 |
| abstract_inverted_index.occurs | 221 |
| abstract_inverted_index.showed | 215 |
| abstract_inverted_index.trials | 228 |
| abstract_inverted_index.(O-VEN) | 118 |
| abstract_inverted_index.(R-VEN) | 109 |
| abstract_inverted_index.0.001). | 191 |
| abstract_inverted_index.Chronic | 123 |
| abstract_inverted_index.between | 202 |
| abstract_inverted_index.chronic | 3 |
| abstract_inverted_index.disease | 126 |
| abstract_inverted_index.factors | 47, 139 |
| abstract_inverted_index.overall | 54 |
| abstract_inverted_index.treated | 36, 178, 194, 244 |
| abstract_inverted_index.without | 188, 206 |
| abstract_inverted_index.Methods: | 57 |
| abstract_inverted_index.Patients | 1 |
| abstract_inverted_index.Results: | 86 |
| abstract_inverted_index.analyses | 70 |
| abstract_inverted_index.centers. | 66 |
| abstract_inverted_index.clinical | 15 |
| abstract_inverted_index.elevated | 129 |
| abstract_inverted_index.included | 61 |
| abstract_inverted_index.leukemia | 5 |
| abstract_inverted_index.negative | 232 |
| abstract_inverted_index.patients | 35, 63, 101, 105, 114, 177, 193, 203, 238 |
| abstract_inverted_index.regimens | 39 |
| abstract_inverted_index.reported | 225 |
| abstract_inverted_index.setting, | 43 |
| abstract_inverted_index.survival | 50, 55 |
| abstract_inverted_index.developed | 102 |
| abstract_inverted_index.incidence | 30 |
| abstract_inverted_index.outcomes. | 16, 85 |
| abstract_inverted_index.pneumonia | 32, 78, 182, 207, 217 |
| abstract_inverted_index.pulmonary | 125 |
| abstract_inverted_index.regimens, | 98 |
| abstract_inverted_index.treatment | 81, 95, 220 |
| abstract_inverted_index.especially | 236 |
| abstract_inverted_index.event-free | 49 |
| abstract_inverted_index.following: | 27 |
| abstract_inverted_index.frequently | 223 |
| abstract_inverted_index.infections | 10 |
| abstract_inverted_index.performed, | 73 |
| abstract_inverted_index.pneumonia. | 254 |
| abstract_inverted_index.real-world | 42, 213 |
| abstract_inverted_index.venetoclax | 219 |
| abstract_inverted_index.Neutropenia | 247 |
| abstract_inverted_index.Univariable | 67 |
| abstract_inverted_index.creatinine, | 130 |
| abstract_inverted_index.development | 76 |
| abstract_inverted_index.lymphocytic | 4 |
| abstract_inverted_index.multicenter | 59 |
| abstract_inverted_index.neutropenia | 92 |
| abstract_inverted_index.obstructive | 124 |
| abstract_inverted_index.susceptible | 8 |
| abstract_inverted_index.1.08–2.78, | 155 |
| abstract_inverted_index.1.10–4.11, | 162 |
| abstract_inverted_index.1.16–3.74, | 148 |
| abstract_inverted_index.2.18–5.89, | 169 |
| abstract_inverted_index.Conclusions: | 211 |
| abstract_inverted_index.complication | 90 |
| abstract_inverted_index.registration | 227 |
| abstract_inverted_index.multivariable | 69 |
| abstract_inverted_index.splenomegaly, | 128 |
| abstract_inverted_index.(COPD)/asthma, | 127 |
| abstract_inverted_index.pneumonia—50 | 103 |
| abstract_inverted_index.respectively). | 173 |
| abstract_inverted_index.venetoclax-based | 38, 80, 97 |
| abstract_inverted_index.Relapsed/refractory | 174 |
| abstract_inverted_index.Background/Objectives: | 0 |
| abstract_inverted_index.rituximab-plus-venetoclax | 108 |
| abstract_inverted_index.obinutuzumab-plus-venetoclax | 117 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 95 |
| corresponding_author_ids | https://openalex.org/A5085929018 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 14 |
| corresponding_institution_ids | https://openalex.org/I385303915 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.75 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.83053204 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |